Výsledky vyhledávání - "Antonello Abbattista"

Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease

Autor: Sai-Hong I. Ou, Benjamin J. Solomon, Alice T. Shaw, Shirish M. Gadgeel, Benjamin Besse, Ross A. Soo, Antonello Abbattista, Francesca Toffalorio, Robin Wiltshire, Alessandra Bearz

Publikováno v: Journal of Thoracic Oncology. 17:568-577

Lorlatinib, a potent, selective third-generation ALK tyrosine kinase inhibitor (TKI), exhibited overall and intracranial antitumor activity in patients with ALK-positive NSCLC.Retrospective analyses in the ongoing phase 2 trial (NCT01970865) investig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7941d33c40288721ea8b9933362060a1
https://doi.org/10.1016/j.jtho.2021.12.011

Zobrazit plný text záznamu

Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies

Autor: Ibiayi Dagogo-Jack, Antonello Abbattista, John F. Murphy, Stan Krulewicz, Andrew Do, Jennifer Peterson, Jessica J. Lin, Justin F. Gainor, Rossella Messina, Elizabeth A. Krueger, Holger Thurm, Beow Y. Yeap

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 18(1)

The safety profile of lorlatinib includes neurocognitive adverse events (NAEs). Baseline factors associated with developing NAEs remain poorly characterized.Records from patients who received lorlatinib through prospective studies at Massachusetts Ge

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cbb6c86d3749e197f0d4585d5f25487
https://pubmed.ncbi.nlm.nih.gov/36184067

Zobrazit plný text záznamu

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial

Autor: Ross A. Soo, Eng Huat Tan, Hidetoshi Hayashi, Takashi Seto, Chia-Chi Lin, Sai-Hong Ignatius Ou, Dong-Wan Kim, Geoffrey Liu, Antonello Abbattista, Jean-François Martini, Chew Hooi Wong, Francesca Toffalorio, Benjamin J. Solomon

Publikováno v: Lung cancer (Amsterdam, Netherlands). 169

To analyze the efficacy and safety of lorlatinib in Asian and non-Asian patients with pretreated anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) from a phase 1/2 study.In this ongoing phase 2 part of the trial,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88e09fbf25374e3872de5e627cc220be
https://pubmed.ncbi.nlm.nih.gov/35660971

Zobrazit plný text záznamu

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

Autor: Robin Wiltshire, Holger Thurm, Alessandra Bearz, Ben Solomon, Benjamin Besse, Antonello Abbattista, Enriqueta Felip, Todd M. Bauer, D.R. Camidge, Alice T. Shaw, F. Toffalorio, Solange Peters, Jessica Bauman, Gerson Peltz

Publikováno v: Scientia

Lorlatinib; Càncer de pulmó de cèl·lules no petites; ALK TKI de segona generació Lorlatinib; Cáncer de pulmón de células no pequeñas; ALK TKI de segunda generación Lorlatinib; Non-small-cell lung cancer; Second-generation ALK TKIs Backgroun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb4646d7c4532593199c01506e214e5
https://pubmed.ncbi.nlm.nih.gov/33741444

Zobrazit plný text záznamu

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer

Autor: Gerson Peltz, Melissa Lynne Johnson, Enriqueta Felip, Todd M. Bauer, Yazdi K. Pithavala, Holger Thurm, Alice T. Shaw, Alejandro Navarro, Justin F. Gainor, Antonello Abbattista

Publikováno v: Targeted Oncology
Scientia

Background Lorlatinib is a potent, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) designed to penetrate the blood–brain barrier. Objective We report the cumulative incidence of central nervous system (CNS) and non-CNS progression with lo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f944c188b60067850bdd8901d12174d
https://pubmed.ncbi.nlm.nih.gov/32060867

Zobrazit plný text záznamu

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Publikováno v: The Lancet Oncology. 19:1654-1667

Summary Background Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive non-small-cell lung canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::30124db84ef40bde8436e51228a5807a
https://doi.org/10.1016/s1470-2045(18)30649-1

Zobrazit plný text záznamu

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

Autor: Justin F. Gainor, Alice T. Shaw, Jill S. Clancy, Melissa Lynne Johnson, Sophie Postel-Vinay, Benjamin Solomon, Enriqueta Felip, Leonard P. James, Joseph Chen, Benjamin Besse, Alejandro Navarro, Todd M. Bauer, Jorg Dietrich, Antonello Abbattista, Jean-Francois Martini

Publikováno v: The Lancet. Oncology

Summary Background Most patients with anaplastic lymphoma kinase ( ALK )-rearranged or ROS proto-oncogene 1 ( ROS1 )-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably dev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d310de90512d3b2487834f4a2e8462
http://europepmc.org/articles/PMC5777233

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání